Chimeric RNA pp 219-232 | Cite as

SMaRT for Therapeutic Purposes

  • Lisa M. RiedmayrEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 2079)


Spliceosome-mediated mRNA trans-splicing (SMaRT) is a promising strategy for treatment of genetic diseases which cannot be targeted via classical therapy approaches. SMaRT utilizes an exogenous pre-mRNA trans-splicing molecule (PTM) to correct a diseased target pre-mRNA. This process relies on splicing of two separate pre-mRNA molecules in trans creating a mature chimeric mRNA molecule which consists of the protein coding sequence of the PTM as well as the endogenous mRNA. For therapeutic implications, the most critical step in SMaRT is to develop PTMs resulting in a high ratio of trans-splicing to regular cis-splicing.

This protocol provides guidelines on how to design PTMs and describes a fast screening assay to test their efficiencies. To elucidate the therapeutic potential of the best candidates in a more native setting, these PTMs are tested further on mini genes.

Key words

SMaRT Trans-splicing Gene therapy AAV Gene correction Chimeric mRNA 


  1. 1.
    Wu Z, Yang H, Colosi P (2010) Effect of genome size on AAV vector packaging. Mol Ther 18(1):80–86CrossRefGoogle Scholar
  2. 2.
    Olsson JE et al (1992) Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 9(5):815–830CrossRefGoogle Scholar
  3. 3.
    Puttaraju M et al (1999) Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat Biotechnol 17(3):246–252CrossRefGoogle Scholar
  4. 4.
    Berger A et al (2016) mRNA trans-splicing in gene therapy for genetic diseases. Wiley Interdiscip Rev RNA 7(4):487–498CrossRefGoogle Scholar
  5. 5.
    Dooley SJ et al (2018) Spliceosome-mediated pre-mRNA trans-splicing can repair CEP290 mRNA. Mol Ther Nucleic Acids 12:294–308CrossRefGoogle Scholar
  6. 6.
    Berger A et al (2015) Repair of rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new approach for autosomal dominant retinitis pigmentosa. Mol Ther 23(5):918–930CrossRefGoogle Scholar
  7. 7.
    Mearini G et al (2013) Repair of Mybpc3 mRNA by 5′-trans-splicing in a mouse model of hypertrophic cardiomyopathy. Mol Ther Nucleic Acids 2:e102CrossRefGoogle Scholar
  8. 8.
    Lorain S et al (2013) Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches. Nucleic Acids Res 41(17):8391–8402CrossRefGoogle Scholar
  9. 9.
    Brent MR, Guigo R (2004) Recent advances in gene structure prediction. Curr Opin Struct Biol 14(3):264–272CrossRefGoogle Scholar
  10. 10.
    Mansfield SG et al (2003) 5′ exon replacement and repair by spliceosome-mediated RNA trans-splicing. RNA 9(10):1290–1297CrossRefGoogle Scholar
  11. 11.
    Gruber C et al (2011) Spliceosome-mediated RNA trans-splicing facilitates targeted delivery of suicide genes to cancer cells. Mol Cancer Ther 10(2):233–241CrossRefGoogle Scholar
  12. 12.
    Murauer EM et al (2013) A reporter-based screen to identify potent 3′ trans-splicing molecules for endogenous RNA repair. Hum Gene Ther Methods 24(1):19–27CrossRefGoogle Scholar
  13. 13.
    Dallinger G et al (2003) Development of spliceosome-mediated RNA trans-splicing (SMaRT) for the correction of inherited skin diseases. Exp Dermatol 12(1):37–46CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Center for Integrated Protein Science Munich CIPSMLudwig-Maximilians-Universität MünchenMunichGermany
  2. 2.Department of Pharmacy, Center for Drug ResearchLudwig-Maximilians-Universität MünchenMunichGermany

Personalised recommendations